Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLC-001 for steroid-dependent or refractory idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation
jRCT2063220014Phase 2Completed
- Sponsor
- Human Life CORD
- Start
- Oct 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HLC-001 in Idiopathic Pneumonia Syndrome (IPS) and respiratory complication, sponsored by Human Life CORD. Primary endpoint: Overall survival rate on day 56 after treatment. Started Oct 2022; status: completed.
02
Drugs
HLC-001
03
Conditions
Idiopathic Pneumonia Syndrome (IPS)respiratory complication
Beyond the preview
Go deeper on jRCT2063220014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063220014.